Shelia M. Violette, Chief Scientific Officer of Q32 Bio Inc. (NASDAQ:QTTB), filed a Form 4 on August 27, 2026, disclosing the automatic sale of 2,798 shares of common stock on August 25, 2026, to cover tax withholding obligations arising from the vesting of restricted stock units.

Key Highlights

  • Transaction type: 2,798 shares of Q32 Bio Inc. common stock were disposed of (transaction code S) at $16.56 per share on August 25, 2026.
  • Purpose: According to the filing, the sales "were automatic and not in the discretion of the Reporting Person" and represent shares required to cover tax withholding on vesting restricted stock units.
  • Direct holdings after transaction: Violette beneficially owned 127,771 shares directly following the reported transaction.
  • Indirect holdings: An additional 36,277 shares are held indirectly through Violette Holdings LLC, of which Violette is a manager.
  • Disclaimer on indirect shares: The filing states Violette "disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein, if any."
  • Signatory: The form was signed by Eric Bell as Attorney-in-Fact on August 27, 2026.

Q32 Bio CSO Tax-Related Share Sale Details and Beneficial Ownership

According to the Form 4 filed with the SEC on August 27, 2026, Shelia M. Violette, serving as Chief Scientific Officer of Q32 Bio Inc., disposed of 2,798 shares of the company's common stock on August 25, 2026, at a price of $16.56 per share. The filing specifies that these shares were sold automatically to satisfy tax withholding requirements connected with the vesting of restricted stock units, and that the sales were not made at the discretion of Violette.

Following the transaction, Violette directly held 127,771 shares of Q32 Bio Inc. common stock, according to the filing. An additional 36,277 shares are reported as indirectly held through Violette Holdings LLC, an entity for which Violette serves as manager. The filing notes that Violette disclaims beneficial ownership of the Violette Holdings LLC shares beyond any pecuniary interest she may hold, and that the report "shall not be deemed an admission that she is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose."

No derivative securities transactions were reported in Table II of the filing. The Form 4 was filed as an individual report by one reporting person and was not identified as an amendment to a prior filing.

What Was Disclosed

The filing discloses an automatic, non-discretionary sale of 2,798 common shares by Q32 Bio Inc.'s Chief Scientific Officer at $16.56 per share on August 25, 2026, to cover RSU vesting tax obligations, with resulting direct ownership of 127,771 shares and indirect ownership of 36,277 shares through Violette Holdings LLC.